Mutant‑selective, irreversible EGFR tyrosine kinase inhibition of EGFR T790M suppresses downstream signaling (e.g., MAPK/PI3K‑AKT), leading to growth inhibition and apoptosis of the mutant EGFR–expressing tumor cells.